Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

38.02 +0.93 (+2.50%)

Streaming Delayed Price Updated: 2:08 PM EDT, Sep 14, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,738,551
Open	37.66
Bid (Size)	38.10 (1,100)
Ask (Size)	38.73 (400)
Prev. Close	37.09
Today's Range	37.00 - 39.22
52wk Range	18.21 - 38.37
Shares Outstanding	1,110,352,397
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars ↗

Today 10:02 EDT

Teva Pharmaceutical Industries (NYSE:TEVA) said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics...

Via MarketBeat

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

Today 8:03 EDT

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Performance

YTD	+22.8%	+22.8%
1 Month	+3.4%	+3.4%
3 Month	+12.8%	+12.8%
6 Month	+29.0%	+29.0%
1 Year	+101.3%	+101.3%

More News

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

September 10, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Announces Launch of Offering of Senior Notes

September 07, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

September 04, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study ↗

September 02, 2026

Via MarketBeat

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

September 02, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September

September 01, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

August 31, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

August 28, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

August 19, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

August 11, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva (TEVA) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Via The Motley Fool

Why Teva Pharmaceutical Stock Surged This Week ↗

August 02, 2026

Via The Motley Fool

Teva Pharmaceutical Industries Q2 Earnings Call Highlights ↗

July 30, 2026

Via MarketBeat

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

July 29, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva's Turnaround Is Working. Here's the 1 Thing That Could Send It Soaring Another 50%. ↗

July 26, 2026

Via The Motley Fool

Wall Street Thinks Teva Can Soar Over 60%. Here's Why Analysts Are Right. ↗

July 26, 2026

Via The Motley Fool

Teva Pharmaceutical Industries’ Anti-IL-15 Antibody Shows Promise in Vitiligo Study ↗

July 12, 2026

Via MarketBeat

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗

July 09, 2026

Via The Motley Fool

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

July 09, 2026

From Polpharma Biologics International AG

Via Business Wire

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

July 09, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

July 07, 2026

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗

July 06, 2026

Via The Motley Fool

Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? ↗

June 19, 2026

Via The Motley Fool

Frequently Asked Questions

Is Teva Pharmaceutical Industries Limited Ordinary Shares publicly traded?

Yes, Teva Pharmaceutical Industries Limited Ordinary Shares is publicly traded.

What exchange does Teva Pharmaceutical Industries Limited Ordinary Shares trade on?

Teva Pharmaceutical Industries Limited Ordinary Shares trades on the New York Stock Exchange

What is the ticker symbol for Teva Pharmaceutical Industries Limited Ordinary Shares?

The ticker symbol for Teva Pharmaceutical Industries Limited Ordinary Shares is TEVA on the New York Stock Exchange

What is the current price of Teva Pharmaceutical Industries Limited Ordinary Shares?

The current price of Teva Pharmaceutical Industries Limited Ordinary Shares is 38.02

When was Teva Pharmaceutical Industries Limited Ordinary Shares last traded?

The last trade of Teva Pharmaceutical Industries Limited Ordinary Shares was at 09/14/26 02:08 PM ET

What is the market capitalization of Teva Pharmaceutical Industries Limited Ordinary Shares?

The market capitalization of Teva Pharmaceutical Industries Limited Ordinary Shares is 42.21B

How many shares of Teva Pharmaceutical Industries Limited Ordinary Shares are outstanding?

Teva Pharmaceutical Industries Limited Ordinary Shares has 42B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.